SIK2

Across TCGA pan-cancer cohorts, SIK2 RNA differs between tumor and matched normal tissue in 10 of 18 cancer types tested, making tumor–normal expression one of SIK2’s most consistent transcriptional readouts.

The strongest signal is observed in thyroid carcinoma (THCA), where SIK2 RNA is repressed in tumor relative to normal tissue. In most cancer types SIK2 is over-expressed in tumor, although a few such as THCA and LUAD show the opposite, repressed pattern.

THCA, LUAD, and LUSC are the cancer types where SIK2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SIK2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
THCA	Male	All	−0.878	<.001	9	view →
LUAD	Female	II,III,IV	−1.281	<.001	8	view →
LUSC	All	II,III,IV	−1.236	<.001	8	view →
BLCA	Male	All	−1.031	<.001	7	view →
BRCA	All	III,IV	−1.954	<.001	6	view →
KIRP	Male	All	−0.787	<.001	6	view →
LIHC	All	All	+0.436	.001	5	view →
KIRC	Male	All	−0.318	.003	3	view →
UCEC	All	All	−0.642	.001	2	view →
KICH	All	All	−0.483	.013	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 10 strongest of 10 lineages.

SIK2–THCA

Open the THCA breakdown →